WHAT IS CLAIMED IS:

- 1. A method of preparing a lyophilized composition comprising:
 - (a) mixing
 - (i) a polyoxyethylene (POE) and polyoxypropylene (POP) block copolymer;
 - (ii) a polynucleotide;
 - (iii) a cationic surfactant; and
 - (iv) an amorphous cryoprotectant or a crystalline bulking agent;

at a temperature below the cloud point of said block copolymer to form a mixture; and

- (b) lyophilizing the mixture.
- 2. The method of claim 1, wherein said block copolymer is of the general formula:

 $HO(C_2H_4O)_x(C_3H_6O)_y(C_2H_4O)_xH$; wherein (y) represents a number such that the molecular weight of the hydrophobic POP portion (C_3H_6O) is up to approximately 20,000 daltons and wherein (x) represents a number such that the percentage of the hydrophilic POE portion (C_2H_4O) is between approximately 1% and 50% by weight.

3. The method of claim 1, wherein said block copolymer is of the general formula:

HO $(C_3H_6O)_y(C_2H_4O)_x(C_3H_6O)_yH$; wherein (y) represents a number such that the molecular weight of the hydrophobic POP portion (C_3H_6O) is up to approximately 20,000 daltons and wherein (x) represents a number such that the percentage of the hydrophilic POE portion (C_2H_4O) is between approximately 1% and 50% by weight.

4. The method of claim 1, further comprising a cold filtration step.

- 5. The method of claim 1, wherein said mixing step (a) is performed at a temperature of about -2°C to about 8°C.
- 6. The method of claim 4, wherein said cold filtration step is performed at a temperature of about -2°C to about 8°C.
- 7. The method of claim 4, wherein said cold filtration step is performed using a filter with a pore size of about 0.01 microns to about 2 microns.
- 8. The method of claim 2, wherein said block copolymer is CRL-1005.
- 9. The method of claim 1, wherein the cationic surfactant is selected from the group consisting of benzalkonium chloride (BAK), benethonium chloride, cetrimide, cetylpyridinium chloride, acetyl triethylammonium chloride, (±)-N-(Benzyl)-N,N- dimethyl-2,3-bis(hexyloxy)-1-propanaminium bromide (Bn-DHxRIE), (±)-N-(2-Acetoxyethyl)-N,N-dimethyl- 2,3-bis(hexyloxy)-1-propanaminium bromide (DHxRIE-OAc), (±)-N-(2-Benzoyloxyethyl)-N,N-dimethyl-2,3-bis(hexyloxy)-1- propanaminium bromide (DHxRIE-OBz) and (±)-N-(3-Acetoxypropyl)-N,N- dimethyl-2,3-bis(octyloxy)-1- propanaminium chloride (Pr-DOctRIE-OAc).
- 10. The method of claim 1, wherein said mixture comprises at least one amorphous cryoprotectant.
- 11. The method of claim 10, wherein said amorphous cryoprotectant is sucrose.
- 12. The method of claim 1, wherein said mixture comprises at least one crystalline bulking agent.

- 13. The method of claim 1, wherein said mixture comprises about 1% to about 20% (w/v) of said amorphous cryoprotectant or crystalline bulking agent.
- 14. The method of claim 11, wherein the final concentration of sucrose is about 10% (w/v).
- 15. The method of claim 1, wherein said mixture additionally comprises a pH stabilizing physiologic buffer.
- 16. The method of claim 15, wherein said physiologic buffer is selected from the group consisting of: saline, PBS, HEPES, MOPS, BIS-TRIS, sodium phosphate, potassium phosphate, dibasic sodium phosphate (Na₂HPO₄), monobasic sodium phosphate (NaH₂PO₄), monobasic sodium potassium phosphate (NaKHPO₄), magnesium phosphate (Mg₃(PO₄)₂·4H₂O), or D(+)-α-sodium glycerophosphate (HOCH₂CH(OH)CH₂OPO₃Na₂).
- 17. The method of claim 16, wherein said physiologic buffer is sodium phosphate.
- 18. The method of claim 15, wherein the concentration of said physiologic buffer in the mixture is from about 5 mM to about 25 mM.
- 19. The method of claim 17, wherein said sodium phosphate is at a concentration of about 5 mM to about 25 mM.
- 20. The method of claim 1, wherein the final concentration of said cationic surfactant present in said mixture is from about 0.01 mM to about 5 mM.
- 21. The method of claim 1, wherein the final concentration of said block copolymer present in said mixture is from about 1mg/mL to about 50mg/mL.

- 22. The method of claim 1, wherein the final concentration of said polynucleotide molecules present in said mixture is from about 1ng/mL to about 10mg/mL.
- 23. A product produced by the process of claim 1.
- 24. A stable, mono-dispersed product produced by reconstituting the product of claim 23 with an aqueous solution.
- 25. A product produced by the process of claim 4.
- 26. A stable, mono-dispersed product produced by reconstituting the product of claim 25 with an aqueous solution.
- 27. A product produced by the process of claim 15.
- 28. A stable, mono-dispersed product produced by reconstituting the product of claim 27 with an aqueous solution.